Secretome profile of TNF-α-induced human umbilical cord mesenchymal stem cells unveils biological processes relevant to skin wound healing.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING Regenerative medicine Pub Date : 2023-11-01 Epub Date: 2023-09-06 DOI:10.2217/rme-2023-0085

Lihui Tai, Nik Syazana Saffery, Sze Piaw Chin, Soon Keng Cheong

引用次数: 0

Abstract

Aim: To profile and study the proteins responsible for the beneficial effect of the TNF-α-induced human umbilical cord mesenchymal stem cells (hUCMSCs) secretome in wound healing. Methods: The hUCMSCs secretome was generated with (induced) or without (uninduced) TNF-α and was subsequently analyzed by liquid chromatography-mass spectrometry, immunoassay and in vitro scratch assay. Results: Proteomic analysis revealed approximately 260 proteins, including 51 and 55 unique proteins in the induced and uninduced secretomes, respectively. Gene ontology analysis disclosed that differential proteins in the induced secretome mainly involved inflammation-related terms. The induced secretome, consisting of higher levels of FGFb, VEGF, PDGF and IL-6, significantly accelerated wound closure and enhanced MMP-13 secretion in HaCaT keratinocytes. Conclusion: The secretome from induced hUCMSCs includes factors that promote wound closure.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

TNF-α-诱导的人脐带间充质干细胞分泌组谱揭示了与皮肤伤口愈合相关的生物学过程。

目的:研究TNF-α-诱导的人脐带间充质干细胞(hUCMSCs)分泌组对创面愈合有益作用的相关蛋白。方法:用(诱导)或不(未诱导)TNF-α制备hUCMSCs分泌组，并采用液相色谱-质谱法、免疫分析法和体外划痕法进行分析。结果:蛋白质组学分析显示了大约260种蛋白质，其中诱导和未诱导分泌组中分别有51种和55种独特的蛋白质。基因本体论分析表明，诱导分泌组中的差异蛋白主要涉及炎症相关术语。诱导的分泌组由更高水平的FGFb、VEGF、PDGF和IL-6组成，显著加速了HaCaT角化细胞的伤口愈合，增强了MMP-13的分泌。结论:诱导的hUCMSCs分泌组中含有促进伤口愈合的因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.

期刊最新文献

Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold. ATMP clinical trials in the UK. Industry updates from the field of stem cell research and regenerative medicine in September 2024. Correction. Industry updates from the field of stem cell research and regenerative medicine in August 2024.